Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 45,180 shares at $47.03 ($2.1M) on 2023-02-24, disclosed to the SEC on 2023-02-27.
Open-market sale of $2.1M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.03 | 22,590 | $1.1M | 50.0% |
| 2 | $47.03 | 22,590 | $1.1M | 50.0% |
| Total | $47.03 avg | 45,180 | $2.1M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |